Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11959960 | 0.76 | — | — | |
| SCHEMBL22624887 | 0.75 | — | — | |
| SCHEMBL12050713 | 0.71 | — | — | |
| SCHEMBL11455703 | 0.71 | — | — | |
| SCHEMBL939745 | 0.71 | — | — | |
| SCHEMBL22950993 | 0.67 | ALDH1A1 (0.39) | — | |
| SCHEMBL8070359 | 0.67 | ALDH1A1 (0.34) | L3MBTL1 | |
| SCHEMBL20988067 | 0.65 | — | — | |
| SCHEMBL22002825 | 0.64 | — | — | |
| SCHEMBL19919837 | 0.62 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192794-A1 | SUSTAINED HIV PROTEASE INHIBITOR | Shionogi & Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20140315784-A1 | Binding Inhibitors of the Beta. Transducin Repeat-Containing Protein | ITI SCOTLAND LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | L3MBTL1 3126/4885 |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | MB, ALB, BCAT2 | L3MBTL1 156/4885 |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | L3MBTL1 1493/4885 |
| US-20140315784-A1 | Binding Inhibitors of the Beta. Transducin Repeat-Containing Protein | TARDBP, EPS15, TTC14 | L3MBTL1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.